A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
This study is an open-label, multi-center Phase IB/II clinical trial of SHR-9839(sc) combined with anti-tumor therapy in patients with advanced solid tumors, aimed at evaluating the safety, tolerability, and efficacy of SHR-9839(sc) in combination with anti-tumor therapy in patients with advanced solid tumors. Phase IB is the dose escalation stage, and Phase II is the efficacy expansion stage.
Epistemonikos ID: f6947b865e22b91d61b55ab8ca984becef5a48c8
First added on: Nov 18, 2025